Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The biopharma industry has been holding its collective breath all year, wondering what might be coming from the White House.
Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.
A tangled web has been woven at Michigan-based Rockwell Medical. The board of directors has fired the chief executive officer and chief financial officer.
A Los Angeles jury sided with 68-year-old Joanne Anderson, who was diagnosed with mesothelioma allegedly linked to a Johnson & Johnson talc product. It is the second similar award regarding the product.
A former Valeant Pharmaceuticals and a former Philidor Rx Services have been found guilty of using a kickback scheme to defraud the company.
Two months after a setback in the U.S. House of Representatives, Congress has authorized “right to try” legislation.
The mysterious death of a biotech startup chief executive officer in late April projected the term biohacker into the forefront of the industry lexicon.
There are several companies facing decisions by the U.S. Food and Drug Administration (FDA) this upcoming week. However, it should be noted that because the upcoming weekend is the Memorial Day holiday in the United States, some of these decisions may be made before their dates to avoid the holiday. Here’s a look.
Allergan has gone to great lengths to defend the patents for its blockbuster dry-eye drug Restasis and it looks like the company will have to head back to court again.
In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition.